Antengene to Present Preclinical Data on Next-Gen ADCs and TCEs at AACR 2026

Highlights include ATG-125 bispecific ADC, ATG-106 CDH6-targeted TCE, and ATG-112 ALPPL2-targeted TCE

Mar. 18, 2026 at 1:20am

Got story updates? Submit your updates here. ›

Antengene Corporation, a global biotech company, announced it will present results from three preclinical studies on novel antibody-drug conjugates (ADCs) and T-cell engagers (TCEs) at the 2026 American Association for Cancer Research Annual Meeting. The presentations will feature ATG-125, a B7-H3 x PD-L1 bispecific ADC, as well as two investigational TCEs developed using Antengene's proprietary AnTenGager platform - ATG-106 targeting CDH6 for ovarian and kidney cancers, and ATG-112 targeting ALPPL2 for gynecological, digestive, bladder, and lung cancers.

Why it matters

Antengene's pipeline of next-generation ADCs and TCEs represents innovative approaches to treating solid tumors and hematological malignancies. The preclinical data being presented at AACR 2026 highlights the potential of these molecules to simultaneously target tumor cells and modulate the immune system, supporting their further development as potential new therapies for hard-to-treat cancers.

The details

ATG-125 is designed to simultaneously target the immune checkpoint molecules B7-H3 and PD-L1, enabling targeted delivery of a cytotoxic payload while also modulating immune evasion. ATG-106 and ATG-112 are novel "2+1" format TCEs that feature bivalent binding to tumor antigens (CDH6 and ALPPL2 respectively) and a sterically masked CD3 arm to restrict T-cell activation to the tumor microenvironment.

  • The AACR 2026 Annual Meeting will take place from April 17-22, 2026 in San Diego, California.
  • ATG-125 will be presented on April 21, 2026 from 2:00 PM - 5:00 PM Pacific Time (5:00 AM - 8:00 AM April 22 Beijing Time).
  • ATG-106 and ATG-112 will be presented on April 20, 2026 from 9:00 AM - 12:00 PM Pacific Time (12:00 AM - 3:00 AM April 21 Beijing Time).

The players

Antengene Corporation Limited

A global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs.

AnTenGager™ TCE Platform

Antengene's proprietary T cell engager 2.0 platform featuring "2+1" bivalent binding, steric hindrance masking, and proprietary CD3 sequences to minimize cytokine release syndrome and enhance efficacy.

Got photos? Submit your photos here. ›

The takeaway

Antengene's pipeline of innovative ADCs and TCEs leveraging its proprietary platforms represents a promising approach to developing next-generation cancer therapies that can simultaneously target tumor cells and modulate the immune system. The preclinical data being presented at AACR 2026 highlights the potential of these molecules to address unmet needs in solid tumors and hematological malignancies.